Entrectinib

Red

Brand Name(s):

Indication:ROS1-positive advanced non-small-cell lung cancer in adults

Rationale:1,2,8

Considered:Oct-25

Review Date:Oct-25

Comments:
NICE TA643 – Entrectinib is recommended, within its marketing authorisation, as an option for treating ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1 inhibitors.